Skip to main
HSCS

HSCS Stock Forecast & Price Target

HSCS Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

HeartSciences is well-positioned for success with MyoVista Insights, its cloud software platform for ECG data that has already begun commercialization. Additionally, the company has a large market opportunity, as proven by the over 100 million ECG tests performed in the US annually, and multiple potential revenue streams from MyoVista Insights. With a strong monetization framework and a positive risk/reward profile, HeartSciences has the potential to generate substantial revenues and deliver significant upside to investors.

Bears say

HeartSciences is expected to face a prolonged period of low sales and high expenses as they wait for FDA approval for their product, with revenue estimates for FY2026-2027 being lowered to $0.0 million and $0.4 million respectively. While the recent announcement of FDA 510(k) submission for their MyoVista wavECG device is a positive step, it will still take until early 2026 for approval, keeping the company's future prospects uncertain.

HSCS has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Heart Test Laboratories Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Heart Test Laboratories Inc (HSCS) Forecast

Analysts have given HSCS a Strong Buy based on their latest research and market trends.

According to 1 analysts, HSCS has a Strong Buy consensus rating as of May 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Heart Test Laboratories Inc (HSCS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.